Reliability and Validity of Turkish Version of Headache Impact Test (HIT-6) in Patients with Migraine

Pınar YALINAY DİKMEN1, Mumine BOZDAG2, Mumin GÜNEŞ3, Seda KOŞAK1, Bahar TAŞDELEN4, Derya ULUDUZ3, Aynur OZGE5

1Department of Neurology, Acıbadem Mehmet Ali Aydınlar University School of Medicine, İstanbul, Turkey
2Department of Neurology, Tansus State Hospital, Mersin, Turkey
3Department of Neurology, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Turkey
4Department of Biostatistics and Medical Informatics, Mersin University School of Medicine, Mersin, Turkey
5Department of Neurology, Mersin University School of Medicine, Mersin, Turkey

ABSTRACT

Introduction: The Headache Impact Test (HIT-6) is a self-report questionnaire designed to evaluate the impact of headache on quality of life. The aim of this study is to assess reliability and validity of Turkish version of HIT-6 questionnaire in patients with migraine.

Methods: A total of 114 patients with migraine were included in this multicenter, prospective, descriptive study conducted at two consecutive visits 4 weeks apart. Comprehensibility, patient-physician reliability, internal consistency, test-retest reliability and validity of the translated HIT-6 were analyzed.

Results: Patients identified that HIT-6 items were “well-understood” in both visit 1 (ranged from 88.6% to 95.7%) and visit 2 (ranged from 93.0% to 98.2%).

A highly positive correlation (R=0.876, p<0.001) was noted between visit 1 scores related to self-administered and physician-administered HIT-6 scores. Internal consistency analyzed via Cronbach’s α values for visit 1 and visit 2 HIT-6 scores in all patients were 0.753 (acceptable) and 0.864 (excellent), respectively. HIT-6 scores of patients (64.13 (6.20) and 62.70 (7.04), at visits 1 and 2, respectively, p=0.07) showed a moderate test-retest reliability (R=0.437, p=0.0004). The HIT-6 score positively correlated with visit 1 and visit 2 headache severity-Likert scale (R=0.451 and 0.478, respectively, p<0.001) and VAS (R=0.365 and 0.531, respectively p<0.001) scores, and with visit 2 headache days for a month (R=0.215, p=0.022).

Conclusion: These results demonstrated that the Turkish translation is equivalent to English version of HIT-6 in terms of internal consistency and it has moderate test-retest reliability and validity as correlated with headache severity, VAS and headache days for a month.

Keywords: Headache impact test, migraine, quality of life, HIT-6, MIDAS, headache

INTRODUCTION

Migraine is a chronic, neurovascular disease characterized by heterogeneous clinical features with a strong genetic basis (1–3). Though not life-threatening but often detrimental to a patient’s ability to carry out everyday activities, migraines are the third most common disease worldwide, and have been ranked as the sixth highest amongst all other causes of disability (4–7).

Owing to their significant role in accurate diagnosis and appropriate treatment of migraines, the use of Patient Reported Outcome (PRO) tools has been recommended by clinical and regulatory guidelines for better disease management in terms of diagnosis, screening, monitoring of quality of life, as well as identification of disease-related disability and selection of appropriate treatment (8–11).

For migraine patients, there are two PRO tools that have been widely used in clinical practice and trials (12–14): Headache Impact Test (HIT-6) and Migraine Disability Assessment questionnaire (MIDAS). For disability assessment, MIDAS was developed to cover the three activity domains, which include schoolwork, jobs, and household chores, as well social, leisure, and family activities (12). The reliability and validity of MIDAS were demonstrated by Stewart et al. (12, 15, 16). Ertas et al. were performed reliability and validity of the Turkish MIDAS in 2004 (17).

The HIT-6 is a brief questionnaire designed by Bayliss et al. to assess migraine pain from the patient’s point of view and to track lost time (work, school work, housework, social activities) (18). Both tools are scientifically valid measurements of migraine severity, and are also used to evaluate treatment effectiveness (19).

HIT-6 is considered to be a more subjective tool, as it reflects patients’ own evaluation of headache severity on their quality of life. MIDAS, on the other hand, is more objective compared to HIT-6, as it questions the frequency of days affected by headaches rather than the disability expressed by the patients themselves (20). Moreover, in addition to covering a wider swath of the headache spectrum than MIDAS, HIT-6 has only six questions enabling easier completion of the patient’s task and a shorter recall period (19–21).
The translation process for HIT-6, performed by Gandek et al. in 2003 in terms of comparability of the content of the 27 translations involved, revealed HIT-6 to be relatively easier to translate, and was deemed to be clearer and more relevant by the respondents (22). However, while after the translation stage, psychometric properties and equivalence of the HIT-6 were examined for 11 languages in 14 countries (Brazilian Portuguese, UK English, Canadian English, Hungarian, Spanish, Dutch, Finnish, French, German, Greek and Hebrew) (14), the reliability and validity of the Turkish version of HIT-6 has not yet been studied. Hence, while the Turkish translation of HIT-6 has been available as an assessment tool for patients with migraines in daily clinical practice since 2003, it has rarely been used for research. For the current study, the English version of HIT-6 was translated to Turkish once again, instead of using the 2003 version of Turkish translation.

This study was therefore designed to assess the efficacy of the Turkish translation as it compared to its original (English) version, based on assessing the patient-physician reliability, test-retest reliability, internal consistency, comprehensibility and validity of the Turkish version of HIT-6 the questionnaire in patients dealing with chronic and episodic migraines.

**METHODS**

**Study Population**

Between November 2017 and April 2018, multicenter, prospective, and descriptive studies were conducted at three headache centers in Turkey, and included 114 adults diagnosed with migraines. Migraine diagnosis was made by three neurologists (PYD, DU, AO) with expertise in headaches using the International Classification of Headache Disorders criteria, third edition (ICHD3 beta). Patients with episodic or chronic migraines were included in the study, regardless of whether or not they had received preventive oral medication, while for those under preventive oral medication initiation of the treatment for at least three months prior to enrollment was required for the inclusion. The presence of acute and chronic psychosis, mental retardation and illiteracy, lack of follow-up visit or unwillingness to participate were the exclusion criteria. Of 138 patients initially enrolled, 24 patients were excluded due to loss of follow-up (n=14) or unwillingness to participate in the study (n=10) and the final study population subjected to analysis involved 114 patients (Fig 1). Episodic migraines were defined as experiencing an average of up to 14 headache days each month for the past three months. Chronic migraines were defined as headaches occurring ≥15 days per month for a minimum of 3 months, of which ≥8 days met the criteria for a migraine.

Written consent was required from each participant, following a thorough debriefing of the study’s objectives and procedures, carried out according to the ethical principles outlined in the "Declaration of Helsinki" and endorsed by the institutional ethics committee.

**Study Design and Measures**

The study was conducted at two consecutive visits including visit 1 (performed at baseline) and visit 2 (performed 4-weeks after the visit 1). Data on sociodemographic and headache characteristics and MIDAS scores were recorded at visit 1, and patients were asked to return the headache diaries for visit 2. All patients were assessed for visual analogue scale (VAS) for pain intensity. Likert scale for headache severity during daily activities and self-administered scores on comprehensibility assessment form (CAF) and HIT-6 at both visits. Physician-reported CAF scores and physician-administered HIT-6 were also recorded at visit 1 for a subgroup of patients (subgroup A, n=57) who were selected via 1:1 randomization of overall study population. Comprehensibility, validity, test-retest reliability and, patient-physician reliability, and internal consistency of the translated HIT-6 were analyzed (Figure 1).

**Severity Frequency and Intensity of Headache**

Assessment of the severity of patients’ headaches was made using a 4-point Likert scale scored from (0) no, (1) mild, (2) moderate and (3) severe pain. The frequency of headaches was monitored using headache diaries at visit 2 and MIDAS-A scores at visit 1, while headache intensity of the patients was assessed using VAS scores at visit 1 and visit 2 along with MIDAS-B scores at visit 1.

**MIDAS**

MIDAS consists of five questions measuring headache related disability during three activities (school, or paid work; household chores; family, social or leisure activities) covering the past 3 months. The final total score sums the number of missed days for the abovementioned activities, and categorizes the disability in relation to attack severity as, none or minor disability (scores 0–5), mild disability (scores 6–10), moderate disability (scores 11 to 20) or severe disability (scores ≥21) (12, 15–17). Besides the five listed above, the two other questions were not included in the score, but gave relevant information to the clinician regarding headache frequency (MIDAS A) and pain intensity (MIDAS B) over the past three months (12, 15–17).

**HIT-6**

HIT-6 items include areas such as vitality, pain, and psychological distress, as well as social, role, and cognitive functioning. Three of 6 items specifically address the previous 4 weeks, while no time period is specified for the remaining 3 questions. Each item is answered using a 5-point Likert scale (6=never, 8=seldom, 10=occasionally 11=very often, 13=always). The final score is determined from the summation of six items, with a range between 36 and 78, with higher scores indicating greater impact, as categorized into four groups including scores ≤49 (little or no impact), scores 50–55 (some impact), scores 56–59 (substantial impact) and scores ≥60 (severe impact) (18, 23) (Figure 2).

**Forward and Back Translations of HIT-6**

For adaptation of the HIT-6 into Turkish, translation and back-translation methods were used. As for the first step, a native Turkish speaker with fluent English translated the original (English) version into Turkish. And then, a native English speaker translated the Turkish version back into English. The back-translated English version was read and compared with the original HIT-6 in English by two of the authors (PYD, AO), and only then was the Turkish version accepted as the final form of Turkish version of HIT-6 (Figure 3).

**Comprehensibility Assessment**

Comprehensibility of HIT-6 was assessed using CAF based on self-administered scores in all patients at both visits, and also on physician-
HEADACHE IMPACT TEST- HIT-6

To complete, please check one answer for each question.

1. When you have headaches, how often is the pain severe?

| NEVER | RARELY | SOMETIMES | VERY OFTEN | ALWAYS |
|-------|--------|-----------|------------|--------|

2. How often do headaches limit your ability to do usual daily activities including household work, work, school, or social activities?

| NEVER | RARELY | SOMETIMES | VERY OFTEN | ALWAYS |
|-------|--------|-----------|------------|--------|

3. When you have a headache, how often do you wish you could lie down?

| NEVER | RARELY | SOMETIMES | VERY OFTEN | ALWAYS |
|-------|--------|-----------|------------|--------|

4. In the past 4 weeks, how often have you felt too tired to do work or daily activities because of your headaches?

| NEVER | RARELY | SOMETIMES | VERY OFTEN | ALWAYS |
|-------|--------|-----------|------------|--------|

5. In the past 4 weeks, how often have you felt fed up or irritated because of your headaches?

| NEVER | RARELY | SOMETIMES | VERY OFTEN | ALWAYS |
|-------|--------|-----------|------------|--------|

6. In the past 4 weeks, how often did headaches limit your ability to concentrate on work or daily activities?

| NEVER | RARELY | SOMETIMES | VERY OFTEN | ALWAYS |
|-------|--------|-----------|------------|--------|

(6 points each) (6 points each) (6 points each) (6 points each) (6 points each)

To score, add points for answers in each column.

TOTAL SCORE

You should share your results with your doctor. Headaches that stop you from enjoying the important things in life, like family, work, school or social activities could be migraine.

Figure 2. English version of HIT-6

administered scores in subgroup A at visit 1. Each item of HIT-6 was assessed for how well the patient understood the questions as score 1 (well-understood), score 2 (partly understood), score 3 (hardly understood) and score 4 (not understood). The physicians also filled in the form for the patients of subgroup A. During the study period, CAF scores were taken at visit 1 and visit 2, and were then compared to see if there was any change in the patients’ comprehensibility level, while the correlation between the visit 1 self-administered and physician-administered scores were also analyzed.

Patient-Physician Reliability

The correlation between self-administered and physician-administered HIT-6 scores at visit 1 was also analyzed in the subgroup A to evaluate the questionnaire’s patient-physician reliability.

Reliability Assessment

Reliability (reproducibility and consistency) was assessed with two different methods including test-retest reliability (the connection between visit 1 and visit 2 HIT-6 scores in each patient) and internal consistency (Cronbach’s alpha values for visit 1 and visit 2 HIT-6 scores in all patients and for visit 1 self-administered and physician administered HIT-6 scores in subgroup A). The correlation between the internal consistency of visit 1 self-administered and physician-administered scores was also analyzed. The 4-week period between visit 1 and 2 was the predetermined time interval, as it was considered brief enough to rule out any major changes in the disease’s severity, and long enough for the patients not to recall their earlier answers from visit 1.

Validity of HIT-6

The validity of HIT-6 was assessed using correlation of HIT-6 scores with headache frequency and intensity parameters including correlations with MIDAS, MIDAS-A, MIDAS-B, headache severity-Likert scale and VAS scores at visit 1 and correlations with headache days for a month (diaries), headache severity-Likert scale and VAS scores at visit 2.
Statistical Analysis
The data were processed and analyzed using STATISTICA 13.3 statistical package. The demographic characteristics of patients were summarized as mean, standard deviations (SD), counts and percentages. Normality assumptions of HIT, MIDAS, MIDAS-A, MIDAS-B, Likert scale and VAS were checked by Shapiro Wilk test. Separate samples t-test and paired t-test were used to analyze HIT-6 scores identified by patients vs. physicians and recorded at visit 1 vs. visit 2 among patients, respectively. The Pearson correlation method was used to measure test-retest validity and reliability, and the correlation results were given as Pearson correlation coefficient (R). The internal consistency of HIT-6 scores for the patients and the physicians were assessed using Cronbach's $\alpha$, and the correlation between internal consistencies of patients' and physicians' HIT-6 scores were studied using the split-half reliability assessment. Cronbach's $\alpha$, values higher than 0.7 and 0.8 were thought to indicate an acceptable and excellent internal consistency. Statistically, $p<0.05$ was deemed to be significant.

RESULTS
Clinical Characteristics and Demographics
The study involved 114 patients [mean (SD) age: 35.8 (9.2) years; 60.5% were females] diagnosed with migraine for an average 11.4 years. The majority of participants was classified as episodic migraine (67.5%) and 37.7% of patients were on preventive treatment at study enrollment (Table 1).

Overall Headache Scale Scores
In the overall study population, while no significant change was observed from visit 1 to visit 2 for severity of headache - Likert scale [2.1 (0.6) vs. 1.9 (0.8); $p=0.07$], VAS scores changed significantly from visit 1 to visit 2 [7.5 (0.7) vs. 6.8 (2.0); $p=0.001$] (Table 1).

Patients with chronic migraine had significantly higher MIDAS scores at visit 1 [63.7 (42.8) vs. 18.3 (16.4); $p<0.001$], higher severity of headache-
Table 1. Demographic and clinical characteristics and overall headache scale scores

| Patient Demographics | All Patients | n (%) |
|----------------------|-------------|-------|
| Gender (female)      | 60          | 60.5  |
| Age (year), mean (SD)| 35.9 (9.2)  |       |

| Migraine Characteristics | Episodic | Chronic |
|--------------------------|----------|---------|
| Type of migraine, n (%)  | 77 (67.5)| 37 (32.5)|
| Duration of migraine (years), mean (SD) | 11.4 (8.8)|
| Family history for migraine, n (%) | 44 (38.6)|
| Preventive treatment, n (%) | 43 (37.7)|
| Number of NSAID intake per month, mean (SD) | Visit 1: 7.9 (9.8) | Visit 2: 5.7 (7.8) | Visit 1: 1.2 (2.7) | Visit 2: 1.1 (2.8) |
| Number of triptan intake per month, mean (SD) | Visit 1: 6 (5.3) | Visit 2: 3 (2.6) | Visit 1: 2 (1.8) | Visit 2: 1.2 (2.7) |

| Headache (severity, frequency, intensity) scores, mean (SD) | Total | MIDAS A | MIDAS B |
|-------------------------------------------------------------|-------|---------|---------|
| MIDAS scores- visit 1, mean (SD)                            | 26.9 (23) | 28.7 (23) | 7.1 (1.6) |
| Likert scale- Severity of headache                          |       |         |         |
| Visit 1                                                      | 2.1 (0.6) |         |         |
| Visit 2                                                      | 1.9 (0.8) |         |         |
| p value                                                      | 0.07   |         |         |
| VAS score                                                    |       |         |         |
| Visit 1                                                      | 7.5 (0.7) |         |         |
| Visit 2                                                      | 6.8 (2.0) |         |         |
| p value                                                      | 0.001* |         |         |

NSAID: Non-steroidal anti-inflammatory drugs, SD: Standard deviation, VAS: Visual Analogue Scale, MIDAS: Migraine Disability Assessment Scale, MIDAS A: Headache frequency over a three-month course and MIDAS B: Pain intensity (0= no pain; 10= very severe pain) over a three-month course. The severity of headache upon to patient's daily activities was assessed using a 4-point Likert scale as (0) no, (1) mild, (2) moderate and (3) severe, *= p<0.05

Paired t test

Table 2. Comprehensibility of HIT-6 items for visit 1 vs. visit 2 application by patients and for visit 1 application by patients vs. physicians

| HIT-6 Items (self-administered scores) | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 |
|----------------------------------------|--------|--------|--------|--------|--------|--------|
| Visit 1                                | 101 (88.6) | 106 (93.0) | 109 (95.6) | 112 (98.2) | 109 (95.6) | 110 (96.5) |
| Visit 2                                | 105 (90.4) | 107 (92.1) | 105 (92.4) | 112 (98.3) | 108 (94.7) | 111 (97.4) |
| Student's t test, p value              | 0.003 | <0.001 | <0.001 | 0.1395 | 0.006 | <0.001 |

HIT-6: Headache Impact Test, R: Pearson correlation coefficient, *= p<0.05

"Paired t test,"*Independent samples t-test,"*Pearson correlation analysis

Table 3. Comprehensibility of HIT-6 items for visit 1 vs. visit 2 application by patients and for visit 1 application by patients vs. physicians

| HIT-6 Items (self-administered and physician-administered scores at visit 1) | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 |
|------------------------------------------------------------------------------|--------|--------|--------|--------|--------|--------|
| Self-reported                                                                 | 49(86.0) | 55(96.5) | 55(96.5) | 56(98.2) | 53(93.0) | 56(98.2) |
| Physician-reported                                                           | 55(96.5) | 55(96.5) | 56(98.2) | 52(91.2) | 56(98.2) | 53(93) |
| Student's t test, p value                                                    | 0.024 | 0.317 | 0.317 | 0.083 | 0.180 | 0.180 |

HIT-6: Headache Impact Test, R: Pearson correlation coefficient, *= p<0.05

"Paired t test,"*Independent samples t-test,"*Pearson correlation analysis

Comprehensibility

Patients identified that HIT-6 items were "well-understood" at both visit 1 (ranged from 88.6% to 95.7%) and visit 2 (ranged from 93% to 98.2%). Physician-based evaluation at visit 1 also revealed high rates for "well-understood" items by patients (ranged from 96.5 to 98.2%) (Table 2).

There were significant correlations between patient and physician assessments on comprehensibility for all items (R ranged from 0.3539 to 0.6593; p ranged 0.006 to <0.001) except for item 4 (Table 2).

Higher rates for "well-understood" was identified by patients in visit 2 than in visit 1 [98.3% vs. 90.4%; p=0.006] for item 4 and by physicians as compared with patients [96.5% vs. 86.0%; p=0.024] for item 1 at visit 1 (Table 2).

Patient-Physician Reliability

Visit 1 scores related to self-administered and physician-administered HIT-6 scores showed no statistically significant difference (p=0.0928) but a highly positive correlation (r=0.876, p<0.001) (Table 3).

Internal Consistency

Internal consistency analyzed via Cronbach’s α values for visit 1 and visit 2 HIT-6 scores in all patients were 0.753 (acceptable) and 0.864 (excellent), respectively (Table 3).
Significant correlation was observed between HIT-6 score and visit 1 and also with visit 2 headache days for a month (R=0.215, p=0.022). No severity - Likert Scale [R=0.451 and 0.478, respectively; p<0.001 for each]. The HIT-6 score was positively correlated with visit 1 and visit 2 headache days or less from visit 1 to visit 2 was chosen to test-retest reliability, and thus the probable negative effect of severity change on the results was eliminated. Mean (SD) HIT-6 scores of aforementioned patients [64.13 (6.20) and 62.70 (7.04), at visits 1 and 2, respectively; p=0.0765] showed a moderate test-re-test reliability (R=0.437, p=0.0004) (Table 3).

Validity of HIT-6

The HIT-6 score was positively correlated with visit 1 and visit 2 headache severity - Likert Scale [R=0.451 and 0.478, respectively; p<0.001 for each] and VAS [R=0.365 and 0.531, respectively; p<0.001] for each scores, and also with visit 2 headache days for a month (R=0.215, p=0.022). No significant correlation was observed between HIT-6 score and visit 1 MIDAS scores (Table 4).

### DISCUSSION

Our conclusions on the validity and reliability of the Turkish translation of HIT-6 with migraine patients in a clinical setting ranged from acceptable to excellent (R=0.753 and 0.864) internal consistency, moderate test-re-test reliability (R=0.437) and validity as correlated with headache severity, VAS and headache days for month of the questionnaire in Turkish patients.

In a psychometric analysis of 11 HIT-6 translations across 14 countries, most translations (Hungarian, Canadian English, Greek, Portuguese, German, Spanish, French, UK English, Dutch, and Hebrew) were reported to be comparable to U. S. English and adequately reliable in all languages with the Cronbach α coefficients above the 0.70 criterion (14).

Similarly, our findings indicate that the internal consistency of HIT-6 was acceptable (0.753) at visit 1 and excellent (0.864) at visit 2 in all patients. This seems also in accordance with previous HIT-6 studies which indicated a good internal consistency of HIT-6 with Cronbach α values ranging from 0.75 to 0.92 (13, 20, 24, 25).

Our findings also revealed high patient-physician reliability (R=0.876) and a moderate test-re-test reliability (R=0.437) of HIT-6. Although test-re-test reliability values for HIT-6 has been reported to range from 0.77 to 0.80 in most studies (13, 20, 24, 25), a moderate level of test-retest reliability (R=0.50) was also reported in patients with migraines or tension type headache (26).

In addition to those stated above, our findings support the sufficiency of the range of HIT-6 scores in determining the level of headache-related disability of the patients who seek headache-specialty care and its potential to measure headache impact (14, 24).

In our cohort, HIT-6 had excellent comprehensibility for at least 90% of patients at both visits, while two items showed a significant difference between visits among patients (item 4) and between patients and physicians in visit 1 (item 1). Specifically, item 4 ("In the past 4 weeks, how often have you felt too tired to do work or daily activities because of your headaches?") was well-understood by higher percentage of patients in visit 2 than in visit 1 (98.3% vs. 90.4%, p=0.006), while percentage of

### Table 3. Test-retest reliability and internal consistency of HIT-6

| Subgroup A (n=57) | HIT-6 scores Mean (SD) | p value\(^a\) (Visit 1 vs. visit 2) | Test-Retest Reliability Correlation between scores\(^a\) | Reliability (internal consistency) (Cronbach-alpha coefficient) |
|-------------------|------------------------|-----------------------------------|-----------------------------------------------|--------------------------------------------------|
| Visit 1 self-administered | 64.54 (5.30) | 0.928 | 0.876 | <0.001 | 0.689 |
| Visit 1-physician administered | 65.08 (5.48) | | | | 0.673 |
| Subgroup A (n=57) | Visit 1 | | | | |
| | Visit 2 | | | | |
| All patients (n=114) | Visit 1 | 64.13 (6.20) | 0.0765 | 0.437 | 0.0004 | 0.753 |
| | Visit 2 | 62.70 (7.04) | | | | 0.864 |
| Subgroup A (n=57) | Visit 1 | 64.54 (5.30) | 0.053 | 0.4042 | 0.021 | 0.689 |
| | Visit 2 | 62.64 (7.94) | | | | 0.896 |
| Remaining patients (n=57) | Visit 1 | 63.71 (7.02) | 0.291 | 0.5025 | 0.005 | 0.803 |
| | Visit 2 | 62.74 (6.08) | | | | 0.809 |

HIT-6: Headache Impact Test, R: Pearson correlation coefficient, SD: Standard deviation, *= p<0.05

\(^a\)Paired t test, \(^b\)Independent samples t-test, \(^c\)Pearson correlation analysis

### Table 4. Validity of HIT-6

| VISIT | Correlation of HIT-6 scores | r | p |
|-------|----------------------------|---|---|
| MIDAS | 0.150 | 0.375 |
| MIDAS-A | 0.016 | 0.927 |
| MIDAS-B | 0.234 | 0.163 |
| Headache severity-Likert Scale | 0.451 | <0.001 |
| VAS | 0.365 | <0.001 |
| VISIT 2 | r | p |
| Headache days for a month | 0.215 | 0.022 |
| Headache severity-Likert scale | 0.478 | <0.001 |
| VAS | 0.531 | <0.001 |

HIT-6: Headache Impact Test, MIDAS: Migraine Disability Assessment Scale, MIDAS A: Headache frequency over a three-month course and MIDAS B: Pain intensity (0= no pain; 10= very severe pain) over a three-month course. The severity of headache upon to patient's daily activities was assessed using a 4-point Likert scale as (0) no, (1) mild, (2) moderate, (3) severe.

Pearson correlation analysis; R: Pearson correlation coefficient, *= p<0.005
patients who well-understood item 1 ("When you have headaches, how often is the pain severe?") was considered to be higher by physicians administered than by patients themselves (subgroup A) [96.5% vs. 86.0%; p=0.024] in visit 1. In addition, there were significant correlations between patient and physician assessments on comprehensibility for all items [R ranged from 0.3593 to 0.6593, p ranged from 0.006 to <0.001] except for item 4. This seems notable given the consideration of item 4 of HIT-6 to measure the least headache impact with lesser likelihood of discerning differences in headache severity clinically (14).

The VAS scores of our patients were significantly changed from visit 1 to visit 2, so a subgroup of patients whose number of days with headache changed 3 days or less from visit 1 to visit 2 was chosen to test-retest reliability to eliminate the potential impact of change in severity on the results. The mean (SD) HIT-6 scores of this subgroup of patients were similarly high in visit 1 and visit 2 [64.54 (5.30) vs. 62.64 (7.94); p=0.053] with a good correlation of scores between visits (R=0.4042, p=0.021). This seems to indicate on the basis of HIT-6 scores that all participants suffered from severe disability due to migraine in both visits. In our study, severe disability due to headache was evident for both visits not only in chronic migraine patients but also in episodic migraine patients. Accordingly, our findings support the past study on psychometric properties of HIT-6 translated to several languages which indicated that scale means of HIT-6 were similar across languages, being 64.30 on average and above 60 for all languages, highlighting a likelihood of headaches to have a very severe impact on participants in all countries (14).

HIT-6 was reported to be correlated significantly with total MIDAS (R=0.56), headache pain severity (R=0.46) and number of headache days per month (R=0.26), while also considered to be a valid instrument to make distinction for headache impact between episodic and chronic migraine (20).

In our cohort, HIT-6 score was positively correlated with headache severity - Likert scale [R=0.451 and 0.478, respectively] and VAS (R=0.365 and 0.531, respectively) scores at visit 1 and visit 2, and also with visit 2 headache days for a month (R=0.215), whereas no significant correlation was noted between HIT-6 score and visit 1 MIDAS scores. Nonetheless, it should be noted that while both MIDAS questionnaire and the HIT-6 are PRO tools, the aspects of headache-related disability [objective/lost time due to headache in MIDAS whereas, subjective/impact of headaches on patients’ life in HIT-6] and constructs assessed by the two instruments is considered to differ as is the used recall period (3 months vs. 1-month, respectively) (20).

In addition, our findings indicate that HIT-6 cannot differentiate between chronic migraine and episodic migraine in Turkish population, while other scales used to evaluate headache intensity and frequency (MIDAS, Likert scale or VAS) were able to discriminate for episodic vs. chronic type of migraine for at least one visit.

 Nonetheless, while no significant difference was noted between chronic and episodic migraine patients in terms of HIT-6 scores at both visits, a significant change from baseline HIT-6 scores was noted only among episodic migraine patients. Similarly, Persian HIT-6 was also reported to be a valid and reliable questionnaire for the evaluation of headache, whereas authors noted that it cannot differentiate between chronic migraine, episodic migraine, and tension-type headache in Iranian population (26).

Certain limitations to this study should be taken into consideration. First, we relied on the patients’ memory for the headache frequency, which was determined based on items A of MIDAS, which requires remembering headache frequency over a 3-month time period. Hence, while 77 (67.5%) and 37 (32.5%) patients were classified into episodic and chronic migraine categories at visit 1, re-classification of patients based on completed headache diaries for a past month at visit 2 revealed 92 (80.7%) and 22 (19.3%) patients to be classified as episodic and chronic migraine, respectively. This finding emphasizes the fluctuating nature of migraine frequency, and thus underlines the importance of headache diaries for accurate diagnosis of migraine types, as well as for selection of therapy and monitoring of therapeutic response. Second, participation of lower number of chronic vs. episodic migraine patients in this study might have affected the results of correlation analysis between MIDAS and HIT-6 scores, as well as the potential of HIT-6 to differentiate migraine types. Third, given the significant change in VAS scores from visit 1 to visit 2, test-retest reliability was carried out in a subgroup of patients with up to 3 days change in the frequency of headache days from baseline visit to eliminate the possible detrimental effects of fluctuating frequency and level of severity of migraine attacks on the study findings.

To sum up, in terms of internal consistency, these results indicate that the Turkish translation is equivalent to the English version of HIT-6, while there is moderate test-retest reliability and validity as correlated with headache severity - Likert scale, VAS and headache days for a month. The Turkish translation of HIT-6 proved to be just as valid when used by physicians in determining the impact of headaches as a patient-reported outcome tool self-administered by both episodic and chronic migraine patients. However, HIT-6 seems not to be able to discriminate for episodic vs. chronic type of migraine in Turkish patients with migraine, which seems to be possible for MIDAS, Likert scale-headache severity or VAS instruments for at least at one session.

**Ethics Committee Approval:** The principles stated in the “Helsinki Declaration” were followed and approved by the Acibadem University, School of Medicine ethics committee (Date:26.10.2017, Number: 2017-16/15).

**Informed Consent:** Written approval was obtained from each participant according to the ethical principles approved by the corporate ethics committee.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept- PYD, DU, AJ; Design- PYD, BT, DU, AJ; Supervision- PYD, DU, AJ; Resource- PYD, MB, MG, SK, BT, DU, AO; Materials- PYD, MB, MG, SK, BT, DU, AO; Data Collection and/or Processing- PYD, MB, MG, SK, BT, DU, AO; Analysis and/or Interpretation- PYD, MB, MG, SK, BT, DU, AO; Literature Search- PYD, MB, MG, SK, BT, DU, AO; Writing- PYD, MB, MG, SK, BT, DU, AO; Critical Reviews- PYD, DU, AO.

**Conflict of Interest:** The authors declare that they have no conflict of interest.

**Financial Disclosure:** None.

**REFERENCES**

1. De Vries B, Frants RR, Ferrari MD, van den Maagdenberg AM. Molecular genetics of migraine. Hum Genet 2009;126:115–132. [Crossref]
2. Lipton RB, Serrano D, Pavlovic JM, Manack AN, Reed ML, Turkel CC, Buse DC. Improving the classification of migraine subtypes: An empirical approach based on factor mixture models in the American MigrainePrevalence and Prevention (AMPP) study. Headache 2014;54:830–849. [Crossref]
3. Mulder EJ, Van Baal, Gaist D, Kallela M, Kaprio J, Svensson DA, Nyholt DR, Martin NG, MacGregor AJ, Cherkas LF, Boomsma DI, Palotie A. Genetic and environmental influences on migraine: A twin study across six countries. Twin Res 2003;6:422–431. [Crossref]
4. Steiner TJ, Stovner LJ, Vas T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain 2016;17:104. [Crossref]
5. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017;16:877–897. [Crossref]
6. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211–1259. [Crossref]
7. Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lanieri-Miniet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, Andréé C. The impact of headache in Europe: Principal results of the Euroquality project. J Headache Pain 2014;15:31. [Crossref]
8. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2—assessing respondent understanding. Value Health 2011;14:978–988. [Crossref]

9. Hareendran A, Mannix S, Skalicky A, Bayliss M, Blumenfeld A, Buse DC, Desai PR, Ortmeier BG, Sapra S. Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine— the migraine physical function impact diary (MPPID). Health Qual Life Outcomes 2017;15:224. [Crossref]

10. Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ. Task Force of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28:484–495. [Crossref]

11. Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C, Sandrini G, Steiner T, Winter PB. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765–786. [Crossref]

12. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001;56:520–528. [Crossref]

13. Rendas-Baum R, Yang M, Varon SF, Bloudek LM, DeGryse RE, Kosinski M. Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine. Health Qual Life Outcomes 2014;12:117. [Crossref]

14. Martin M, Blaisdell B, Kwong JW, Bjorner JB. The Short-Form Headache Impact Test (HIT-6) was psychometrically equivalent in nine languages. J Clin Epidemiol 2004;57:1271–1278. [Crossref]

15. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, Sawyer J. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999;53:988–994. [Crossref]

16. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000;88:41–52. [Crossref]

17. Ertaş M, Siva A, Dalkara T, Uzuner N, Dora B, Inan L, Idiman F, Sarica Y, Selçuki D, Sirin H, Oğuzhanoğlu A, İrkeç C, Ozmenoğlu M, Ozbenli T, Ozturk M, Saip S, Neyal M, Zariñoğlu M. Turkish MIDAS group. Validity and reliability of the Turkish Migraine Disability Assessment (MiDAS) questionnaire. Headache 2004;44:786–793. [Crossref]

18. Bayliss MS, Dewey JE, Dunlap L, Batenhorst AS, Cady R, Diamond M, Shefyll F. A study of the feasibility of Internet administration of a computerized health survey. The headache impact test (HIT). Qual Life Res 2003;12:953–961. [Crossref]

19. Dowson AJ. Assessing the impact of migraine. Curr Med Res Opin 2001;17:298–309. [Crossref]

20. Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. Cephalalgia 2011;31:357–367. [Crossref]

21. Mannix S, Skalicky A, Buse DC, Desai P, Sapra S, Ortmeier B, Widnell K, Hareendran A. Measuring the impact of migraine for evaluating outcomes of preventative treatment for migraine headaches. Health Qual Life Outcomes 2016;14:143. [Crossref]

22. Gandek B, Alacoque J, Uzun V, Andrew-Hobbs M, Davis K. Translating the Short-Form Headache Impact Test (HIT-6) in 27 countries: Methodological and conceptual issues. Qual Life Res 2003;12:975–979. [Crossref]

23. Bayliss M, Batenhorst A. The HIT-6™ A User Guide. USA, Lincoln, RI: QualityMetric Inc.; 2002.

24. Kawata AK, Coeytaux RR, De Vellis RF, Finkel AG, Mann D, Kahn K. Psychometric Properties of the HIT-6 among patients in a headache-specialty practice. Headache 2005;45:638–643. [Crossref]

25. Kosinski M, Bayliss MS, Bjorner JB, Ware JE, Garber WH, Batenhorst A, Cady R, Dahlof CG, Dowson A, Tepper S. A six-item short-form survey for measuring headache impact: The HIT-6™. Qual Life Res 2003;12:963–974. [Crossref]

26. Zandifar A, Banihashemi M, Haghdoost F, Masjedi SS, Manouchehri N, Asgari F, Najafi MR, Ghorbani A, Zandifar S, Saadatnia M, White MK. Reliability and Validity of the Persian HIT-6 Questionnaire in Migraine and Tension-type Headache. Pain Pract 2014;14:625–631. [Crossref]